Uploaded September 2021 | Updated September 2026, 1 week ago
The controversy over the FDA’s approval of Aducanumab for the treatment of Alzheimer’s disease continues – both over the evidence supporting the drug’s efficacy as well as the FDA’s approval process. Some insurers have declared their ambivalence about paying for the medication, and several prominent health systems have said that they will not administer it.
In this week’s Medical Grand Rounds, Gil Rabinovici (Professor in the Department of Neurology) and Rita Redberg (Professor in the Division of Cardiology at UCSF Health) will discuss the clinical and biomarker evidence for disease modification by aducanumab and explain the regulatory issues of accelerated approvals and the Medicare coverage process for injectable drugs. The session will be guest moderated by Dept. of Neurology chair Andy Josephson.
Note: Closed captions will be available within 48-72 hours after posting.
Program
Andrew Josephson: Introduction
00:03:35-00:25:40 – Clinical & Policy Implications of Aducanumab: Gil Rabinovici (Professor in the UCSF Department of Neurology)
00:25:40-00:44:15 – Rita Redberg (Professor in the Division of Cardiology at UCSF Health)
0:44:15-00:58:32 – Q&A with Gil Ravinovici and Rita Redberg
Andrew Josephson: Closing
See previous DOM Medical Grand Rounds:
September 16: Clinical Problem Solving
youtu.be/gmjuWWOs40I
September 9: The Fourth Surge, Vaccines, Boosters, Schools, and More youtu.be/cKJkC3MLcDg
August 12: The Fourth Surge, Delta Variant, Vaccines, Boosters, and More youtu.be/-sQsIETW47Q
June 17: The Delta Variant, and Lessons from the Pandemic (with Andy Slavitt) youtube.com/watch?v=xR-LbraMlgs
See all UCSF Covid-19 grand rounds, which have been viewed over 2.5M times, here: https://medicine.ucsf.edu/covid-19_grand_rounds.
The controversy over the FDA’s approval of Aducanumab for the treatment of Alzheimer’s disease continues – both over the evidence supporting the drug’s efficacy as well as the FDA’s approval process. Some insurers have declared their ambivalence about paying for the medication, and several prominent health systems have said that they will not administer it.
In this week’s Medical Grand Rounds, Gil Rabinovici (Professor in the Department of Neurology) and Rita Redberg (Professor in the Division of Cardiology at UCSF Health) will discuss the clinical and biomarker evidence for disease modification by aducanumab and explain the regulatory issues of accelerated approvals and the Medicare coverage process for injectable drugs. The session will be guest moderated by Dept. of Neurology chair Andy Josephson.
Note: Closed captions will be available within 48-72 hours after posting.
Program
Andrew Josephson: Introduction
00:03:35-00:25:40 – Clinical & Policy Implications of Aducanumab: Gil Rabinovici (Professor in the UCSF Department of Neurology)
00:25:40-00:44:15 – Rita Redberg (Professor in the Division of Cardiology at UCSF Health)
0:44:15-00:58:32 – Q&A with Gil Ravinovici and Rita Redberg
Andrew Josephson: Closing
See previous DOM Medical Grand Rounds:
September 16: Clinical Problem Solving
youtu.be/gmjuWWOs40I
September 9: The Fourth Surge, Vaccines, Boosters, Schools, and More youtu.be/cKJkC3MLcDg
August 12: The Fourth Surge, Delta Variant, Vaccines, Boosters, and More youtu.be/-sQsIETW47Q
June 17: The Delta Variant, and Lessons from the Pandemic (with Andy Slavitt) youtube.com/watch?v=xR-LbraMlgs
See all UCSF Covid-19 grand rounds, which have been viewed over 2.5M times, here: https://medicine.ucsf.edu/covid-19_grand_rounds.
